scholarly journals Effects of intravenous immunoglobulin therapy on patients of guillain barré syndrome in intensive care unit of BSMMU - a retrospective study

2009 ◽  
Vol 21 (2) ◽  
pp. 72-75
Author(s):  
Debasish Banik ◽  
Qumrul Huda ◽  
Labib Imran Faruque ◽  
Md Abdul Hye
Keyword(s):  
Retrospective Study ◽  
Early Phase ◽  
Average Duration ◽  
Immunoglobulin Therapy ◽  
Guillain Barre Syndrome ◽  
Intravenous Immunoglobulin Therapy ◽  
Duration Of Stay ◽  
Guillain Barré Syndrome ◽  
Life Threatening ◽  
Guillain Barré

Acute polyneuropathy or Guillain Barré syndrome (GBS) following respiratory, gastrointestinal and other illness cause a world wide morbidity and mortality. Immunotherapy (IgG) is early phase of GBS is supposed to reduce life threatening complications. In our retrospective study in ICU, BSMMU Dhaka from January 2007 to December 2008, we included 43 patients admitted during that time. Among the patients 15 patients who received IgG therapy, 1 (one) patient died and 8 patients died among 28 who did not receive Immunotherapy. Recovery rate was 91.66% among IgG group and 66.67% in non IgG group. Ventilated Patients were 53.33% in IgG group and 71.43% patients were in non IgG group. The average duration of stay was 35 days in IgG group and 39.18 days in non-IgG group. The average duration of stay was 22.57 days in IgG group who received immunotherapy in 0-4 days of onset of symptoms and 45.88 days in who got immunotherapy in 5-8 days of onset of symptoms. It is clearly evident that IgG therapy in early phase of GBS reduces, morality, morbidity and duration of hospital (ICU) stay and IgG therapy in early phase of GBS is a better treatment option. Key Words: GBS, immunoglobulin. Journal of BSA, 2008; 21(2): 72-75

Does intravenous immunoglobulin therapy in Guillain-Barré syndrome patients interfere with serological Zika detection?

2019 ◽  
Vol 18 (6) ◽  
pp. 632-633
Author(s):  
Anupama Karnam ◽  
Emmanuel Stephen-Victor ◽  
Mrinmoy Das ◽  
Laurent Magy ◽  
Jean-Michel Vallat ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Guillain Barre Syndrome ◽  
Intravenous Immunoglobulin Therapy ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Paralytic ileus as the presenting symptom for Guillain–Barré syndrome: a case report

2019 ◽  
Vol 48 (4) ◽  
pp. 030006051989316
Author(s):  
Kuang-Heng Lee ◽  
Tsung-Han Ho ◽  
Jiunn-Tay Lee ◽  
Li-Fan Lin ◽  
Wei-Chou Chang ◽  
...  
Keyword(s):  
Paralytic Ileus ◽  
Early Recognition ◽  
Early Stage ◽  
Immunoglobulin Therapy ◽  
Guillain Barre Syndrome ◽  
Rapid Progression ◽  
Limb Weakness ◽  
Intravenous Immunoglobulin Therapy ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Guillain–Barré syndrome (GBS) is an acute neuroimmunological disorder characterized by rapidly ascending symmetrical limb weakness, areflexia, and sensory deficits. Approximately 65% of patients with GBS present with autonomic dysfunction, which commonly occurs in advanced stages. However, paralytic ileus, a sign of gastrointestinal dysautonomia, is rare as the presenting feature in GBS before motor weakness becomes evident. We report the case of a 54-year-old man admitted to the Emergency Department with paralytic ileus as the prodromal feature in early-stage GBS. Total parenteral feeding and prokinetic use were initiated, but no clinical improvement was observed. The patient showed rapid progression to quadriplegia, which was ultimately determined to be respiratory muscle failure requiring mechanical ventilation and intensive care unit admission. He underwent 5 days of intravenous immunoglobulin therapy and muscle strength was partially improved thereafter. However, the patient’s enteral nutritional support was undesirable because of persistent poor gastric emptying complicated by fungemia and profound sepsis throughout the hospital course. Finally, he died 1 month after admission. Ignorance of this unusual prodrome to GBS could result in delayed treatment, along with potential progression to life-threatening events. Early recognition of GBS and prompt immunotherapy are critical for reducing morbidity and mortality.

scholarly journals A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment

2021 ◽  
Vol 9 ◽  
pp. 232470962110374
Author(s):  
Tomoyo Oguri ◽  
Shinji Sasada ◽  
Satoko Shimizu ◽  
Risa Shigematsu ◽  
Yumi Tsuchiya ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
The Body ◽  
Guillain Barre Syndrome ◽  
Stevens Johnson Syndrome ◽  
Intravenous Immunoglobulin Therapy ◽  
Johnson Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Epidermal Necrosis

A 76-year-old man was admitted to our hospital with Guillain-Barré syndrome (GBS), presenting with facial palsy, dysarthria, and dysphagia as Grade 3 immune-related adverse events (irAEs) due to pembrolizumab administration for Stage IV lung adenocarcinoma. Although prednisolone (1 mg/kg) was started for GBS due to the irAE, dark erythema and skin eruptions appeared on the patient’s torso. Then erosion was observed on 18% of the body surface area and skin biopsy was performed. Finally, the patient was diagnosed with Stevens-Johnson syndrome/toxic epidermal necrosis overlap. Intravenous immunoglobulin therapy was started, and the skin symptoms improved, with the erosion becoming epithelial. He died of aspiration pneumonia related to GBS, although his neurological symptoms had improved after steroid and intravenous immunoglobulin therapy. This is the first reported case of pembrolizumab-induced GBS and Stevens–Johnson syndrome/toxic epidermal necrosis overlap. It is necessary to be careful that the possibility of other severe irAEs may occur simultaneously.

scholarly journals Clinical Outcome of Intravenous Immunoglobulin in the treatment of Guillain Barre Syndrome in a Nepalese Tertiary Centre

2019 ◽  
Vol 2 (1) ◽  
pp. 133-137
Author(s):  
Rajeev Ojha ◽  
Ragesh Karn
Keyword(s):  
Intravenous Immunoglobulin ◽  
Axonal Neuropathy ◽  
Immunoglobulin Therapy ◽  
University Teaching ◽  
Guillain Barre Syndrome ◽  
Disability Score ◽  
Acute Motor Axonal Neuropathy ◽  
Intravenous Immunoglobulin Therapy ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Introduction: Intravenous Immunoglobulin is an approved therapy for Guillain Barre Syndrome. Our objective is to understand the management and outcome in Guillain Barre Syndrome patients treated with Immunoglobulin.Materials and Methods: All consecutive patients were retrospectively evaluated in the study were of age ≥16 years and were being admitted in the department of Neurology of Tribhuvan University Teaching Hospital, Kathmandu, Nepal from 2016 March to 2017 February.Results: A total of 46 patients were included, mean age= 36.5±16.2 years, range = 16years to 80 years. Thirty-two patients (70%) were axonal variant, acute motor axonal neuropathy is more common (18 patients). Intravenous immunoglobulin was used in 23 patients (50%), 17 of them were axonal variant and 6 were demyelinating. Guillain Barre Syndrome patients with bilateral facial weakness (70% vs 30%; p<0.05) were likely to receive immunoglobulin therapy. Patients with immunoglobulin were found to have higher ODSS at Nadir (9.3±1.8 vs 6.9±1.9; p <0.001) and discharge than patients without immunoglobulin treatment (6.2±1.7 vs 5.0±1.6; p=0.001). At Nadir, Patients with immunoglobulin were found to have higher Guillain Barre Syndrome disability score (4.1±0.7 vs 3.2±0.9; p<0.095). In immunoglobulin group, Axonal variants were found to havehigher ODSS score (9.6±1.9 vs 8.2±0.9, p=0.027) and Guillain Barre Syndrome disability score (4.2±0.7 vs 3.5±0.5; p=0.019) at nadir than demyelinating group.Conclusions: Intravenous Immunoglobulin is easier to administer and is safe with fewer adverse effects. Although expensive, it is an effective treatment option in a resource-limited center. Axonal variants are clinically severe and likely to be need of Intravenous Immunoglobulin therapy.

Sign in / Sign up

Export Citation Format

Share Document